Comparison of Mycoplasma hyopneumoniae and porcine circovirus 2 commercial vaccines efficacy when applied separate or combined under experimental conditions

M Sibila, G Guevara, R Cuadrado, P Pleguezuelos, D Pérez, A Pérez de Rozas, E Huerta, A Llorens, O Valero, M Pérez, C López, R Krejci, J Segalés, M Sibila, G Guevara, R Cuadrado, P Pleguezuelos, D Pérez, A Pérez de Rozas, E Huerta, A Llorens, O Valero, M Pérez, C López, R Krejci, J Segalés

Abstract

Background: Mycoplasma hyopneumoniae (Mhyo) and Porcine circovirus 2 (PCV-2) are two of the most significant infectious agents causing economic losses in the weaning to slaughter period. Due to their similar vaccination age, the objective of this study was to assess the efficacy of two already existing Mhyo (Hyogen®) and PCV-2 (Circovac®) vaccines when administered separately or combined (RTM) by means of Mhyo or PCV-2 experimental challenges.

Results: Seven groups of animals were included in the study, being three of them challenged with PCV-2, three with Mhyo and one composed of non-challenged, non-vaccinated pigs. Within each experimental challenge, non-vaccinated (NV) groups were compared with double vaccinated groups using the commercial products separated (VS) or combined (VC). Both vaccinated groups showed significant differences for most parameters measured regarding PCV-2 (serology, percentage of infected animals and viral load in tissues) and Mhyo (serology and gross lesions) when compared to NV groups. VS and VC offered similar results, being only significantly different the PCV-2 antibody values at different time points (higher in the VS group) of the study, although not at the termination day (21 days post-PCV-2 inoculation).

Conclusion: The present study expands the knowledge on the possibility of using two separate Mhyo and PCV-2 commercial vaccines as a RTM product, which offered equivalent virological, immunological and pathological outcomes as compared to these vaccines when used by separate.

Keywords: Mycoplasma hyopneumoniae; Porcine circovirus 2; Ready-to-mix; Ready-to-use; Vaccine.

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests. R. Krejci is employee of CEVA.

© The Author(s) 2020.

Figures

Fig. 1
Fig. 1
Mean (±SD) PCV-2 S/P ELISA values per treatment group and sampling point. Statistical differences are represented in the table below. Different letters in superscript within a column means p < 0.05
Fig. 2
Fig. 2
PCV-2 QPCR results expressed in percentage of positive serum samples per treatment group and sampling point. Different letters in superscript means p < 0.05
Fig. 3
Fig. 3
Mean PCV-2 copies/mL in PCV-2 QPCR positive samples per treatment group and sampling point
Fig. 4
Fig. 4
Percentage of M. hyopneumoniae seropositive animals per treatment and sampling point. Different superscript letters mean p < 0.05
Fig. 5
Fig. 5
Percentage of animals showing different microscopic lung lesion score (0–4) per treatment group. NV-C had significantly higher number of animals showing a microscopic score ≥ 3 than both vaccinated groups

References

    1. Fablet C, Rose N, Grasland B, Robert N, Lewandowski E, Gosselin M. Factors associated with the growing-finishing performances of swine herds: an exploratory study on serological and herd level indicators. Porcine Health Manag. 2018;4:6. doi: 10.1186/s40813-018-0082-9.
    1. Alarcon P, Rushton J, Wieland B. Cost of post-weaning multi-systemic wasting syndrome and porcine circovirus type-2 subclinical infection in England - an economic disease model. Prev Vet Med. 2013;110(2):88–102. doi: 10.1016/j.prevetmed.2013.02.010.
    1. Segales J. Porcine circovirus type 2 (PCV2) infections: clinical signs, pathology and laboratory diagnosis. Virus Res. 2012;164(1–2):10–19. doi: 10.1016/j.virusres.2011.10.007.
    1. Chae C. Porcine respiratory disease complex: interaction of vaccination and porcine circovirus type 2, porcine reproductive and respiratory syndrome virus, and Mycoplasma hyopneumoniae. Vet J. 2016;212:1–6. doi: 10.1016/j.tvjl.2015.10.030.
    1. Dee S. The porcine respiratory disease complex: are subpopulations important? Swine Health Prod. 1996;4(3):147–149.
    1. Opriessnig T, Gimenez-Lirola LG, Halbur PG. Polymicrobial respiratory disease in pigs. Anim Health Res Rev. 2011;12(2):133–148. doi: 10.1017/S1466252311000120.
    1. Opriessnig T, Thacker EL, Yu S, Fenaux M, Meng XJ, Halbur PG. Experimental reproduction of postweaning multisystemic wasting syndrome in pigs by dual infection with Mycoplasma hyopneumoniae and porcine circovirus type 2. Vet Pathol. 2004;41(6):624–640. doi: 10.1354/vp.41-6-624.
    1. Opriessnig T, Madson DM, Schalk S, Brockmeier S, Shen HG, Beach NM, et al. Porcine circovirus type 2 (PCV2) vaccination is effective in reducing disease and PCV2 shedding in semen of boars concurrently infected with PCV2 and Mycoplasma hyopneumoniae. Theriogenology. 2011;76(2):351–360. doi: 10.1016/j.theriogenology.2011.02.014.
    1. Maes D, Sibila M, Kuhnert P, Segales J, Haesebrouck F, Pieters M. Update on Mycoplasma hyopneumoniae infections in pigs: knowledge gaps for improved disease control. Transb Emerg Dis. 2018;65(Suppl 1):110–124. doi: 10.1111/tbed.12677.
    1. Garza-Moreno L, Segales J, Pieters M, Romagosa A, Sibila M. Acclimation strategies in gilts to control Mycoplasma hyopneumoniae infection. Vet Microbiol. 2018;219:23–29. doi: 10.1016/j.vetmic.2018.04.005.
    1. Segales J. Best practice and future challenges for vaccination against porcine circovirus type 2. Expert Rev Vaccines. 2015;14(3):473–487. doi: 10.1586/14760584.2015.983084.
    1. Hernandez-Caravaca I, Gourgues SF, Rodriguez V, Estrada ED, Ceron JJ, Escribano D. Serum acute phase response induced by different vaccination protocols against circovirus type 2 and Mycoplasma hyopneumoniae in piglets. Res Vet Sci. 2017;114:69–73. doi: 10.1016/j.rvsc.2017.03.006.
    1. Tzika ED, Tassis PD, Koulialis D, Papatsiros VG, Nell T, Brellou G, et al. Field efficacy study of a novel ready-to-use vaccine against Mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm. Porcine Health Manag. 2015;1:15. doi: 10.1186/s40813-015-0006-x.
    1. Park C, Kang I, Seo HW, Jeong J, Choi K, Chae C. Comparison of 2 commercial single-dose Mycoplasma hyopneumoniae vaccines and porcine reproductive and respiratory syndrome virus (PRRSV) vaccines on pigs dually infected with M. hyopneumoniae and PRRSV. Can J Vet Res. 2016;80(2):112–123.
    1. Kaalberg L, Geurts V, Jolie R. A field efficacy and safety trial in the Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use porcine circovirus type 2 and Mycoplasma hyopneumoniae combined vaccine. Porcine Health Manag. 2017;3:23. doi: 10.1186/s40813-017-0070-5.
    1. Sibila M, Fort M, Nofrarias M, Perez de Rozas A, Galindo-Cardiel I, Mateu E, et al. Simultaneous porcine circovirus type 2 and Mycoplasma hyopneumoniae co-inoculation does not potentiate disease in conventional pigs. J Comp Pathol. 2012;147(2–3):285–295. doi: 10.1016/j.jcpa.2012.01.003.
    1. Opriessnig T, Prickett JR, Madson DM, Shen HG, Juhan NM, Pogranichniy RR, et al. Porcine circovirus type 2 (PCV2)-infection and re-inoculation with homologous or heterologous strains: virological, serological, pathological and clinical effects in growing pigs. Vet Res. 2010;41(3):31. doi: 10.1051/vetres/2010003.
    1. Opriessnig T, Xiao CT, Halbur PG, Gerber PF, Matzinger SR, Meng XJ. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naive pigs under experimental conditions. Vaccine. 2017;35(2):248–254. doi: 10.1016/j.vaccine.2016.11.085.
    1. Opriessnig T, Patterson AR, Madson DM, Pal N, Ramamoorthy S, Meng XJ, et al. Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination. Vet Microbiol. 2010;142(3–4):177–183. doi: 10.1016/j.vetmic.2009.09.056.
    1. Michiels A, Arsenakis I, Boyen F, Krejci R, Haesebrouck F, Maes D. Efficacy of one dose vaccination against experimental infection with two Mycoplasma hyopneumoniae strains. BMC Vet Res. 2017;13(1):274. doi: 10.1186/s12917-017-1195-0.
    1. Fort M, Sibila M, Nofrarias M, Perez-Martin E, Olvera A, Mateu E, et al. Porcine circovirus type 2 (PCV2) Cap and Rep proteins are involved in the development of cell-mediated immunity upon PCV2 infection. Vet Immunol Immunopathol. 2010;137(3–4):226–234. doi: 10.1016/j.vetimm.2010.05.013.
    1. Garcia-Morante B, Segales J, Lopez-Soria S, de Rozas AP, Maiti H, Coll T, et al. Induction of mycoplasmal pneumonia in experimentally infected pigs by means of different inoculation routes. Vet Res. 2016;47(1):54. doi: 10.1186/s13567-016-0340-2.
    1. Grau-Roma L, Hjulsager CK, Sibila M, Kristensen CS, Lopez-Soria S, Enoe C, et al. Infection, excretion and seroconversion dynamics of porcine circovirus type 2 (PCV2) in pigs from post-weaning multisystemic wasting syndrome (PMWS) affected farms in Spain and Denmark. Vet Microbiol. 2009;135(3–4):272–282. doi: 10.1016/j.vetmic.2008.10.007.
    1. Lopez-Soria S, Sibila M, Nofrarias M, Calsamiglia M, Manzanilla EG, Ramirez-Mendoza H, et al. Effect of porcine circovirus type 2 (PCV2) load in serum on average daily weight gain during the postweaning period. Vet Microbiol. 2014;174(3–4):296–301. doi: 10.1016/j.vetmic.2014.09.016.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir